<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03222089</url>
  </required_header>
  <id_info>
    <org_study_id>FNF-006</org_study_id>
    <nct_id>NCT03222089</nct_id>
  </id_info>
  <brief_title>Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC</brief_title>
  <official_title>FOLFOXIRI in Combination With GM-CSF and IL-2 (FOLFOXIGIL) Versus FOLFOXIRI as First-line Treatment for Patients With Metastatic Colorectal Cancer: a Phase II Trial by the FNF Team.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized phase II trial of FOLFOXIRI in Combination With GM-CSF and IL-2 (FOLFOXIGIL)
      Versus FOLFOXIRI as First-line Treatment for Patients With Metastatic Colorectal Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The triple drug regimen FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) for
      the first-line treatment of metastatic colorectal cancer has shown a significant increase in
      response rate and overall survival compared to FOLFIRI and FOLFOX. The combination of GOLF
      chemotherapy with GM-CSF and IL-2（GOLFIG regimen） has shown more active than the standard
      FOLFOX chemotherapy in first-line mCRC patients，through the chemoimmunomodulatory effects. SO
      the FOLFOXIGIL chemoimmunotherapy regimen was designed with the same principle to evaluate
      the antitumor frontline efficacy in comparison with the FOLFOXIRI regimen as first-line
      treatment of mCRC patients. This is a multicenter, randomized controlled, double-blind, phase
      II trial.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Another study enrolling the similar group of patient are ongoing
  </why_stopped>
  <start_date type="Anticipated">July 20, 2017</start_date>
  <completion_date type="Anticipated">July 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) rate at 10 months</measure>
    <time_frame>PFS rate at 10 months from study entry</time_frame>
    <description>PFS by investigator-reported measurements according to CT image. PFS was calculated from the day of randomization to the date of first documented progression disease (PD) , or death from any cause.
PD was defined as Overall Response by RECIST criteria v1.1 according to CT image.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>up to 12 months</time_frame>
    <description>CR + PR rate according to the RECIST version 1.1 guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Toxicity assessed using the NCI common toxicity criteria, version 4.01</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>OS was calculated from the date of randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>PFS was calculated from the day of randomization to the date of first documented progression, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QLQ C30)</measure>
    <time_frame>Quality of life was evaluated every 2 weeks during treatment and every 8 weeks during follow up (36 months)</time_frame>
    <description>Scores according to EORTC QLQ-C30 scoring manual</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOXIGIL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The FOLFOXIGIL chemoimmunotherapy regimen is composed by FOLFOXIRI chemotherapy and the immunotherapy of GM-CSF and IL-2.
FOLFOXIRI: Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, repeated every 2 weeks.
GM-CSF 150ug s.c. d3-7; Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.
Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, Repeated every 2 weeks.
Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 165 mg/m² 1-hour IV day 1</description>
    <arm_group_label>FOLFOXIGIL</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <other_name>CPT11</other_name>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>oxaliplatin 85 mg/m² 2-hours IV day 1</description>
    <arm_group_label>FOLFOXIGIL</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <other_name>L-OHP</other_name>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levoleucovorin</intervention_name>
    <description>Levoleucovorin 200 mg/m² 2-hours IV day 1</description>
    <arm_group_label>FOLFOXIGIL</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <other_name>Fusilev</other_name>
    <other_name>l-LV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU 2800 mg/m² 46-hours flat continuous infusion IV</description>
    <arm_group_label>FOLFOXIGIL</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>GM-CSF 150ug s.c. d3-7 , Repeated every 4 weeks.</description>
    <arm_group_label>FOLFOXIGIL</arm_group_label>
    <other_name>Granulocyte Macrophage Colony Stimulating Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.</description>
    <arm_group_label>FOLFOXIGIL</arm_group_label>
    <other_name>Interleukin-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological or cytological documentation of adenocarcinoma of the colon or rectum.

          -  unresectable metastatic disease

          -  age 18 to 75 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower if age 70
             years or younger or ECOG performance status of 0 if age 71 to 75 years

          -  at least one measurable lesion according to Response Evaluation Criteria in Solid
             Tumors (RECIST) criteria measured within 4 weeks prior to registration.

          -  no previous chemotherapy or target therapy for metastatic disease (adjuvant
             chemotherapy for non-metastatic disease is allowed if terminated more than 6 months
             ago).

          -  adequate bone marrow, hepatic and renal function as assessed by the following
             laboratory requirements conducted within 7 days of starting study treatment:

               -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet
                  count ≥ 100 x109/ L, hemoglobin (Hb) ≥9g/ dL.

               -  Total bilirubin ≤ 1.5 x the upper limit of normal (ULN).

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.

               -  Alkaline phosphatase limit ≤ 5x ULN.

               -  Amylase and lipase ≤ 1.5 x the ULN.

               -  Serum creatinine ≤ 1.5 x the ULN.

               -  Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.

        Exclusion Criteria:

          -  previous palliative chemotherapy for metastatic disease

          -  previous chemotherapy including irinotecan or oxaliplatin

          -  symptomatic cardiac disease, myocardial infarction in the last 24 months or
             uncontrolled arrhythmia

          -  active infections

          -  pregnancy or lactation at the time of study entry.

          -  inflammatory bowel disease

          -  major autoimmune diseases

          -  acquired immunosuppression (AIDS or major immunosuppressive agents)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rongbo Lin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fujian Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rongbo Lin</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2017</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

